Fig. 2

ARQ 531 demonstrates in vitro anti-leukemic effect in primary AML. MTS proliferation assay using a human stroma co-culture assay. Primary patient blasts (n = 11–12 pts) were co-cultured with HS5-GFP stroma cells and treated with increasing concentrations of ARQ 531 (a) or gilteritinib (b) for 96 h. FLT3 wild-type (WT) samples (red) and FLT3-ITD (black). Colony-Forming Unit-Granulocyte and Macrophage (CFU-GM) assay. Four primary patient blasts were treated with DMSO or three μM ARQ 531 or 0.1 μM gilteritinib (Gilt.) and then cultured in methylcellulose in duplicate dishes. Number of colonies were counted after 14 days (c)